DED

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Retrieved on: 
torsdag, maj 9, 2024
Pain, Cell, Telecanthus, Endothelium, Tissue, Paratriathlon, DED, Eye, ARVO, Disease, Therapy, Patient, SWAP, Irritation, Regeneration, Annual general meeting, Vaccine

“These early results are important as Fuchs’ Endothelial Cell Dystrophy and Dry Eye Disease are severe diseases with few effective treatments available.

Key Points: 
  • “These early results are important as Fuchs’ Endothelial Cell Dystrophy and Dry Eye Disease are severe diseases with few effective treatments available.
  • The company evaluated a therapeutic approach to stimulate endothelial cell proliferation as human corneal endothelial cells have a limited capacity to regenerate.
  • The lead molecule, a Surrozen Fzd 1/2/7 SWAP antibody, increased proliferation of endothelial cells in vitro in human cells.
  • Currently, there is no epithelial regeneration strategy available as treatment usually consists of anti-inflammatory topical eye drops and tear replacements.

OKYO Pharma Announces Participation in May 2024 Investor Conferences

Retrieved on: 
onsdag, maj 8, 2024
FDA, Pain, DED, NCP

LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced upcoming presentations at two investor conferences in May 2024.

Key Points: 
  • LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced upcoming presentations at two investor conferences in May 2024.

Oculis Reports Q1 2024 Financial Results and Provides Company Updates

Retrieved on: 
onsdag, maj 8, 2024
Dexamethasone, Pain, State, Inflammation, Investment, Refractive surgery, Safety, NDA, OCS, Research, Cataract, DED, AON, Development, IND, Retina, ASCRS, Research and development, Patient, Society, Pharming, CHF, Genotype, DME, Bank statement, Clinical trial, Annual general meeting, Ophthalmology, Pharmaceutical industry

The two ongoing Phase 3 52-week trials, DIAMOND-1 and DIAMOND-2, started as planned in December 2023 and February 2024, respectively.

Key Points: 
  • The two ongoing Phase 3 52-week trials, DIAMOND-1 and DIAMOND-2, started as planned in December 2023 and February 2024, respectively.
  • Concurrently, the Company listed on the Nasdaq Iceland Main Market in addition to Nasdaq Global Market in the U.S.
    Snehal Shah, Pharm.
  • The Company also aims to complete an IND submission for OCS-05 in the U.S. in 2024.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.

MiDROPS® Achieves Pivotal Milestone: Proven Safe and Effective in Phase II Clinical Trial

Retrieved on: 
tisdag, maj 7, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Optical, Pain, Political moderate, Telecanthus, Safety, Tissue, Trial of the century, DED, Visual analogue scale, Patient, BTK, Pharmaceutical industry

This proof-of-concept phase 2 study evaluated the effect of 0.1% TL-925 vs Vehicle, dosed twice daily, in 107 patients with moderate to severe dry eye disease (DED) over 28 days.

Key Points: 
  • This proof-of-concept phase 2 study evaluated the effect of 0.1% TL-925 vs Vehicle, dosed twice daily, in 107 patients with moderate to severe dry eye disease (DED) over 28 days.
  • Both TL-925 and the MiDROPS® vehicle were safe and well-tolerated.
  • Importantly, this is the first clinical study to establish the critical role of Bruton’s tyrosine kinase (BTK) in the pathophysiology of DED.
  • “We are elated to establish this important clinical proof-of concept for MiDROPS® as an eyedrop vehicle.

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

Retrieved on: 
torsdag, maj 2, 2024
FDA, Hydrus, MIGS, Telecanthus, Nature, Refractive surgery, News, Research, Depreciation, Cataract, Security (finance), IOP, DED, Webcast, Growth, Environment, District court, Patent, Intraocular pressure, Patient, Court, Society, Judgement, Glaucoma, Alcon, Ciclosporin, Standard of care, GAAP, Pharmaceutical industry

Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year.

Key Points: 
  • Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year.
  • The jury found that Sight Sciences’ asserted patents were willfully infringed, and awarded monetary damages for past infringement.
  • Sight Sciences reaffirms revenue guidance expectations for full year 2024 of approximately $81.0 million to $85.0 million, representing growth of approximately 0% to 5% growth compared to 2023.
  • Sight Sciences' management team will host a conference call today, May 2, 2024, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Joby Partners with Abu Dhabi to Establish Electric Air Taxi Ecosystem

Retrieved on: 
torsdag, april 25, 2024
Vehicle Technology, Automotive, Air, EV, Electric Vehicles, Transport, Alternative Vehicles, Fuels, Municipality, Smart, Memorandum of understanding, Ecosystem, Investment, Uber, Safety, Travel, Exhibition, Collaboration, GCAA, Yas Marina Circuit, Partnership, DMT, DED, SK Telecom, Joby Aviation, Aviation, Delta Air Lines, SAVI, JoeBen Bevirt, Multimedia, Government, Atmosphere, Economic development, Growth, Amusement park

Joby Aviation, Inc. (NYSE:JOBY), a company developing all-electric aircraft for commercial passenger service, today announced it has signed a multilateral Memorandum of Understanding (MoU) with the Department of Municipalities and Transport - Abu Dhabi (DMT), the Abu Dhabi Department of Economic Development (DED) and the Department of Culture and Tourism - Abu Dhabi (DCT Abu Dhabi) that lays the groundwork for Joby to establish and scale air taxi services in Abu Dhabi and beyond.

Key Points: 
  • Joby Aviation, Inc. (NYSE:JOBY), a company developing all-electric aircraft for commercial passenger service, today announced it has signed a multilateral Memorandum of Understanding (MoU) with the Department of Municipalities and Transport - Abu Dhabi (DMT), the Abu Dhabi Department of Economic Development (DED) and the Department of Culture and Tourism - Abu Dhabi (DCT Abu Dhabi) that lays the groundwork for Joby to establish and scale air taxi services in Abu Dhabi and beyond.
  • View the full release here: https://www.businesswire.com/news/home/20240425195449/en/
    departments to establish an electric air taxi ecosystem in the UAE.
  • The agreement also unlocks the potential for inter-emirate air taxi services, for example between Abu Dhabi and Dubai.
  • We’re looking forward to delivering a fantastic experience for our future customers in Abu Dhabi and we’re excited to be unlocking the potential for zero-emissions flight between Abu Dhabi and Dubai.

Additive Manufacturing in the Semiconductor Industry: New AM Research Report Sees $160M of Market Activity in 2024, Growing to $1.4B in 2032

Retrieved on: 
tisdag, april 23, 2024
MBJ, PBF, Chips Act, 3D Systems, Geography, Microsoft Excel, Coherence, Research, DED, 3D printing processes, 3D, Semiconductor, Macro, Intel, Lam Research, BMD, Electronics, Research report, Applied Materials, ASML, Organization, 3D printing

NEW YORK, April 23, 2024 /PRNewswire/ -- Additive Manufacturing Research (AM Research) has published a new market study titled " 3D Printing for Semiconductors: Market Opportunity Brief ".

Key Points: 
  • NEW YORK, April 23, 2024 /PRNewswire/ -- Additive Manufacturing Research (AM Research) has published a new market study titled " 3D Printing for Semiconductors: Market Opportunity Brief ".
  • "3D Printing for Semiconductors" is packaged as a Market Opportunity Brief, the first in a new product series for AM Research.
  • Each Market Opportunity Brief is accompanied by an Excel file of historical market data as well as a 10-year forecast.
  • This report analyzes the state and outlook for additive manufacturing (AM) technologies to optimize and entrench into the semiconductor industry.

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

Retrieved on: 
tisdag, april 9, 2024
Research, NCP, KOL, ARVO, DED, Pain, FDA

LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled “KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease” originally planned for April 9th, 2024 at 12:00 PM ET until May 2024.

Key Points: 
  • LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled “KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease” originally planned for April 9th, 2024 at 12:00 PM ET until May 2024.
  • The Company is rescheduling its event so that it can incorporate additional key analyses of its clinical data which it plans to present at upcoming ophthalmic conferences.
  • OKYO is planning to make a presentation at “Dry Horizons Symposium Navigating the Future of Dry Eye Research”, an event preceding the Association for Research in Vision and Ophthalmology (ARVO) conference with details provided below.

Verana Health Developing Qdata® Dry Eye Disease, the Largest Real-World Dataset of its Kind

Retrieved on: 
torsdag, april 4, 2024
Prevalence, Dry eye syndrome, ASCRS, SAN, Patient, Ophthalmology, Research, RWD, American Academy, Cataract, DED, Society, Data, Telecanthus, Health, Annual general meeting, Nursing

Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.

Key Points: 
  • Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.
  • “We’re harnessing the power of real-world evidence to transform patient care and expedite the development of crucial therapies,” said Sujay Jadhav, CEO of Verana Health.
  • Dry eye disease affects nearly 16 million Americans , posing significant challenges for patients and ophthalmologists alike.
  • Verana Health remains at the forefront of this transformation, continuously expanding its Qdata offerings to meet the growing needs of life sciences teams and clinicians.

TearSolutions, Inc. Appoints Louis M Alpern, MD, MPH, FACS, FICS to its Board of Directors

Retrieved on: 
onsdag, april 3, 2024
Principal, Harvard Medical School, Alpern, Public, Public health, FICS, Private practice, Telecanthus, Patient, DED, MPH, Therapy, FACS, Frustration, Ophthalmology, Pharmaceutical industry

“Dr.

Key Points: 
  • “Dr.
  • Alpern brings extensive real-world clinical experience treating patients with ocular surface disease, having prescribed or trialed virtually every dry eye treatment available,” said Anil Asrani, President and CEO of TearSolutions.
  • “Dr.
  • He received his Doctor of Medicine from Harvard Medical School and his Master of Public Health from the Harvard School of Public Health.